Company intelligence / Profile preview

Symplmed Pharmaceuticals

Cincinnati, Ohio, United Statessec.gov ↗

Ownership: Private
Employees: ~5
Development stage: Commercial

Overview

Symplmed Pharmaceuticals developed and commercialized fixed-dose combination therapies for hypertension, notably Prestalia® (perindopril arginine + amlodipine), which received FDA approval in January 2015. The company’s proprietary DyrctAxess™ platform enabled direct-to-patient medication delivery and compliance monitoring. In June 2017, the U.S. rights to Prestalia were acquired by Marina Biotech.

Therapeutic areas: Cardiovascular
Modalities: Small moleculeCombination drug (fixed-dose combination)
Industry: Biotech

Partnerships

Servier (development/licensing partner for perindopril/Prestalia)

Beyond the preview

Go deeper on Symplmed Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Symplmed Pharmaceuticals.

Explore the full profile